SCHEMBL6258472

SCHEMBL6258472

CCCCNC(=O)c1cccc(N)c1

nearest known ligand 0.79

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 2/20 0.79
NAAA Q02083 1/20 0.58
L3MBTL1 Q9Y468 2/20 0.56
ALDH1A1 P00352 2/20 0.56
KDM4E B2RXH2 1/20 0.56
GAA P10253 2/20 0.54
MAPT P10636 1/20 0.54
TSHR P16473 1/20 0.54
HTT P42858 1/20 0.54
POLB P06746 1/20 0.51
TP53BP1 Q12888 2/20 0.51
ALOX15 P16050 1/20 0.51
HDAC1 Q13547 1/20 0.50
HDAC2 Q92769 1/20 0.50
KDR P35968 1/20 0.50
LMNA P02545 1/20 0.49
HTR2A P28223 1/20 0.48
HPGD P15428 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15923326 0.94 SMN1; SMN2 (0.69) SMN1; SMN2NAAAL3MBTL1ALDH1A1KDM4E
SCHEMBL9168059 0.94 SMN1; SMN2 (0.69) SMN1; SMN2NAAAL3MBTL1ALDH1A1KDM4E
SCHEMBL9168933 0.94 SMN1; SMN2 (0.69) SMN1; SMN2NAAAL3MBTL1ALDH1A1KDM4E
SCHEMBL658648 0.90 L3MBTL1 (0.69) SMN1; SMN2NAAAL3MBTL1ALDH1A1KDM4E
SCHEMBL12516004 0.90 SMN1; SMN2 (0.62) SMN1; SMN2L3MBTL1ALDH1A1KDM4ETP53BP1
SCHEMBL16117373 0.89 SMN1; SMN2 (1.00) SMN1; SMN2NAAAL3MBTL1ALDH1A1GAA
SCHEMBL10630944 0.87 ALDH1A1 (0.57) SMN1; SMN2L3MBTL1ALDH1A1KDM4EGAA
SCHEMBL12497737 0.85 ALDH1A1 (0.64) SMN1; SMN2ALDH1A1KDM4EGAAMAPT
SCHEMBL2972657 0.84 SMN1; SMN2 (0.84) SMN1; SMN2NAAAL3MBTL1ALDH1A1GAA
SCHEMBL1909677 0.84 KDM4E (0.55) SMN1; SMN2L3MBTL1ALDH1A1KDM4EHPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-1073552-C Benzamides for neurodegenerative disorder treatment CENTAUR PHARMACEUTICALS INC (US) 2001-10-24 CN claimed
CN-1182416-A Benzamides for neurodegenerative disorder treatment CENTAUR PHARMACUETICALS INC (US) 1998-05-20 CN claimed
EP-1581202-A2 METHODS FOR THE TREATMENT OF PAIN AND TRAUMATIC INJURY USING BENZAMIDES AND COMPOSITIONS CONTAINING THE SAME Renovis, Inc. (US) 2005-10-05 EP disclosed
US-6858565-B2 Thermosensitive recording material and novel color developer compounds OJI PAPER CO., LTD. (JP) 2005-02-22 US disclosed
WO-2004060286-A2 METHODS FOR THE TREATMENT OF PAIN AND TRAUMATIC INJURY USING BENZAMIDES AND COMPOSITIONS CONTAINING THE SAME RENOVIS, INC. (US) 2004-07-22 WO disclosed
US-20030040434-A1 Thermosensitive recording material and novel color developer compounds OJI PAPER CO., LTD. (JP) 2003-02-27 US disclosed
EP-1264707-A2 Thermosensitive recording material and novel color developer compounds OJI PAPER CO., LTD. (JP) 2002-12-11 EP disclosed
CN-1073552-C Benzamides for neurodegenerative disorder treatment CENTAUR PHARMACEUTICALS INC (US) 2001-10-24 CN disclosed
EP-1079820-A1 BENZAMIDE THERAPEUTICS FOR THE TREATMENT OF INFLAMMATORY BOWEL DISEASE CENTAUR PHARMACEUTICALS, INC. (US) 2001-03-07 EP disclosed
WO-1999059569-A1 BENZAMIDE THERAPEUTICS FOR THE TREATMENT OF INFLAMMATORY BOWEL DISEASE CENTAUR PHARMACEUTICALS, INC. (US) 1999-11-25 WO disclosed
CN-1182416-A Benzamides for neurodegenerative disorder treatment CENTAUR PHARMACUETICALS INC (US) 1998-05-20 CN disclosed
US-4379819-A OIL SOLUBLE MONOAZO DYE CIBA-GEIGY AG (CH) 1983-04-12 US disclosed